Ignite Creation Date:
2024-05-06 @ 7:50 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02619071
Status:
UNKNOWN
Last Update Posted:
2016-06-28
First Post:
2015-11-30
Brief Title:
ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia
Sponsor:
Institut Paoli-Calmettes
Organization:
Institut Paoli-Calmettes
Study Overview
Official Title:
ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia- CeGAL-IPC 2014-012
Status:
UNKNOWN
Status Verified Date:
2016-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CeGAL
Brief Summary:
Adult acute myeloid leukemia AML is a heterogeneous hematologic malignancy associated with poor prognosis especially after relapse High-throughput genomic studies have highlighted the importance of molecular alteration in the pathophysiology clinical evolution and treatment response of AML In addition identification of specific gene mutation can be targeted by specific inhibitors opening the way to personalized treatments However only a limited number of gene mutations are druggable or actionable highlighting the need for additional information to guide treatment choices Among them new Drug Screening Tests DST allow for the screening of library of hundreds of drugs to ex-vivo patient-derived AML cells Combination of genomic and pharmacologic approaches might therefore improve prediction of drug effects There is an urgent need to bring these approaches into the clinic but feasibility trials are necessary before incorporating them into treatments strategiesThe proposed study is a prospective multicentre feasibility study of a combined chemo-genomic approach in patients with advanced AML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None